Acute myeloid leukaemia
Not recruitingStudy of venetoclax and azacitidine treatment in adults with NPM1-mutated acute myeloid leukemia who experience molecular relapse or disease progression
Study of venetoclax and azacitidine treatment in adults with NPM1-mutated acute myeloid leukemia who experience molecular relapse or disease progression
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineVenetoclax
Italy- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:Fondazione Gimema Franco Mandelli Onlus













